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Background
Mounting evidence suggests that neuronal voltage-gated
CaV1.2 and CaV1.3 L-type calcium channels (LTCCs) can
modulate mood and anxiety behaviors. In CaV1.2 dihy-
dropyridine (DHP)-insensitive mice (CaV1.2DHP-/- mice),
systemic application of the DHP channel activator BAYK
8644 induced pro-depression-like behavior providing evi-
dence for a possible role of CaV1.3 channels in mood
behavior. We therefore explored the role of CaV1.3 LTCCs
in depression- and anxiety-like behaviors using CaV1.3-
deficient mice (CaV1.3-/-). However, CaV1.3-/- mice are
congenitally deaf and it is so far unclear how deafness
affects emotional behavior in mice. We therefore used
another mouse model suffering from congenital deafness,
claudin 14-deficient mice (Cldn14-/-) as a control to
address this question. As CaV1.3 channels are expressed in
the retina we also investigated CaV1.3-/- mice for possible
disturbances in retinal morphology and visual function
that could interfere with behavioral analysis.
Methods
Depression-like behavior was assessed using forced swim
and tail suspension tests (FST and TST) whereas elevated
plus maze (EPM) and stress-induced hyperthermia (SIH)
were performed to test anxiety-like behavior. Morris water
maze, electroretinography and immunofluorescence
stainings were performed to evaluate the consequence on
visual acuity and retinal morphology of CaV1.3 deletion
in CaV1.3-/- mice.
Results
We showed that CaV1.3-/- mice displayed less immobility
in the FST as well as in the TST, indicating an antidepres-
sant-like phenotype. In the EPM, CaV1.3-/- mice entered
the open arms more frequently and spent more time there
indicating an anxiolytic-like phenotype which was, how-
ever not supported in the SIH test. By performing parallel
experiments in Cldn14-/- mice, an influence of deafness
on the antidepressant-like phenotype could be ruled out.
On the other hand, a similar EPM behavior indicative of
an anxiolytic phenotype was also found in the Cldn14-/-
animals. Using electroretinography and visual behavioral
tasks we demonstrated that in mice, CaV1.3 channels do
not significantly contribute to visual function. However,
distinct morphological changes were revealed in synaptic
ribbons in the outer plexiform layer of CaV1.3-/- retinas by
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immunohistochemistry. Although these changes have no
major effects on visual function, they indicate a possible
role of this channel type in structural plasticity at the rib-
bon synapse.
Conclusion
CaV1.3 LTCCs modulate depression-like behavior but are
not essential for visual function. The findings raise the
possibility that selective modulation of CaV1.3 channels
could be a promising new therapeutic concept for the
treatment of mood disorders.
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